A 2003 report found that pregnant women 25 years of age and older who are immune to CMV are much less likely to pass the virus to their babies than younger women who have never been exposed to CMV.
A diagnosis of CMV is usually confirmed by culturing the virus in a sample of the infant's urine.
A similar infection, though slightly more serious, may occur two to four weeks after receiving a blood transfusion containing CMV.
About 0.1 percent of all newborn babies have serious damage from CMV infection occurring while they were developing in the uterus.
About 1 to 2.2 percent of newborns in the United States are infected with CMV.
About 50 percent of all transplant patients develop severe illnesses due to reactivation of dormant CMV infection.
About 8 percent of all mononucleosis cases are due to CMV infection.
Although most infants exposed to CMV before birth develop normally and do not show any symptoms, as many as 6,000 infants who were exposed to CMV before birth are born with serious complications each year.
Antiviral drugs are not used to treat CMV infection in otherwise healthy patients because the drugs have significant side effects that outweigh their benefits.
As of 1998, research was still being done to try to find useful drugs to treat newborn babies suffering from congenital infection with CMV.
Babies can be born infected with CMV, either becoming infected in the uterus (congenital infection) or during birth (from infected cervical secretions).
Babies who contract CMV from their mothers during birth rarely develop any illness from these infections.
Because CMV can cross the placental barrier, initial infection in a pregnant woman can lead to infection of the developing baby.
Blood products can be screened or treated to insure that they do not contain CMV.
Body fluids or tissues can be tested to reveal CMV infection.
Cytomegalovirus (CMV) is a common virus in the herpes virus family.
Cytomegalovirus (CMV) is a virus related to the group of herpes viruses.
Cytomegalovirus (CMV)-A common human virus causing mild or no symptoms in healthy people, but permanent damage or death to an infected fetus, a transplant patient, or a person with HIV.
Exposure to CMV can be serious and even life threatening for mothers and infants whose immune systems are compromised, for example, those receiving chemotherapy or who have HIV/AIDS.
Ganciclovir and foscarnet are antiviral medications that have been used to treat patients with weak immune systems who develop a serious illness from CMV (including retinitis).
German measles (Rubella) and cytomegalovirus (CMV) are examples of maternal infections that may cause birth defects in the unborn child.
However, an unborn baby is at great risk for serious problems when the mother becomes infected with CMV for the first time while pregnant.
However, these tests do not give any information regarding when the CMV infection first occurred.
However, this information is not always particularly helpful because CMV stays dormant in the cells for life.
In 2003, a new high-dose prophylactic (preventive) treatment was being tested to reduce CMV risk in stem cell transplant recipients.
In 2003, researchers in Europe announced a new compound that appeared to be highly effective against CMV infections.
In a healthy person, initial CMV infection often occurs without symptoms and is rarely noticed.
In adults, CMV may cause mild symptoms of swollen lymph glands, fever, and fatigue.
In children, ITP is usually triggered by a virus infection, most often rubella, chickenpox, measles, cytomegalovirus (CMV), or Epstein-Barr virus (EBV).
In people with weakened immune systems, CMV infection can cause more serious and potentially life-threatening illnesses.
In the meantime, the NBS will continue to provide CMV seronegative components when requested for appropriate recipients.
In the United States, about 40 to 60 percent of all adults in the middle- and upper-socioeconomic classes show antibody proof of prior infection with CMV; antibody proof is as high as 80 percent in adults in the lower socioeconomic class.
Infants born prematurely who become CMV infected during birth have a greater chance of complications, including pneumonia, hepatitis, decreased blood platelets.
Infants can become infected with CMV while still in the uterus if the mother becomes infected or develops a recurrence of the infection during pregnancy.
Infection with CMV can cause no symptoms or can be the source of serious illness in people with weak immune systems.
It can be transmitted through body secretions, as well as by sexual contact; some newborns acquire CMV through the mother's breast milk.
It is believed that about 85 percent of the adults in the United States have been infected by CMV at some point in their lives.
Like other herpes viruses, CMV remains inactive (dormant) within the body for life after the initial infection.
Newborns who acquire CMV during the birth process or shortly after birth may develop pneumonia, hepatitis, or various blood disorders.
Occasionally, a first-time infection with CMV may cause a mild illness called mononucleosis.
Of those babies born with congenital CMV infection, about 10 percent to 20 percent ultimately suffer form hearing impairment, eye damage, or problems with intellectual or motor function.
Past or recent infection with cytomegalovirus (CMV) can be identified by antibody tests and CMV can be grown from body fluids.
Prevention of CMV infection in the normal, healthy person involves good hand washing.
Prognosis in healthy people with CMV infection is excellent.
Several maternal-fetal infections are known to increase the risk for CP, including rubella (German measles, now rare in the United States), cytomegalovirus (CMV), and toxoplasmosis.
Some of the more serious types of CMV infections occur in people who have been harboring the dormant virus, only to have it reactivate when their immune system is stressed.
Specific diagnostic tests for autoimmune diseases and viruses (CMV, EBV, and rheumatoid factor or RF) may be performed.
Surviving infants with CMV may suffer from hearing problems (15%) or mental retardation (30%).
Tests to look for special immune cells (antibodies) that are directed specifically against CMV are useful in proving that a person has been infected with CMV.
Those infants who develop birth defects after CMV exposure may have serious, lifelong complications.
While she was still battling oral cancer, her official cause of death was listed as "cardiopulmonary arrest due to liver failure and CMV hepatitis."
Worldwide, about 0.2 to 2.2 percent of all babies are born with congenital CMV infection.
Young patients with negative serology for CMV, who may be candidates for bone marrow transplantation, should receive CMV negative blood products.